Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04852354 · ClinicalTrials.gov registry record
Tissue Collection for Drug Screening and Bioanalysis
A clinical trial of Central Nervous System Tumor, sponsored by Weill Medical College of Cornell University.
- Recruiting
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT04852354: Recruiting study of Central Nervous System Tumor, sponsored by Weill Medical College of Cornell University.
NCT04852354 is a study of Central Nervous System Tumor that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 500 participants, above the 82-participant average among 5 other Central Nervous System Tumor trials with a reported enrollment target (510% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04852354, a study of Central Nervous System Tumor, is actively recruiting participants, sponsored by Weill Medical College of Cornell University.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to improve upon the knowledge currently available about central nervous system (CNS) tumors. We will study the different characteristics of these tumors using tissue samples collected during surgery and post-autopsy. The aim is to create tumor cell lines and models to test how they respond to different drugs. This research will help improve treatment options and identify new targets for therapy.
Primary Outcome
To develop patient-derived tissue cell lines and xenografts
Conditions Studied
Study Locations (1)
New York
- Weill Cornell Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2020-07-22 |
| Est. Completion | 2029-07-22 |
What NCT04852354 shows while recruiting
NCT04852354 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 82-participant average among 5 other Central Nervous System Tumor trials with a reported enrollment target (510% higher).
The record links to 1 condition, with Central Nervous System Tumor appearing as the primary indexed condition, and to 0 interventions.
NCT04852354 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04852354 about?
NCT04852354 is a clinical study titled "Tissue Collection for Drug Screening and Bioanalysis". The purpose of this study is to improve upon the knowledge currently available about central nervous system (CNS) tumors. We will study the different characteristics of these tumors using tissue samples collected during surgery and post-autopsy. The aim is to create tumor cell lines and models to te...
What is the current status of trial NCT04852354?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2020-07-22. Estimated completion is 2029-07-22.
What conditions does trial NCT04852354 study?
This clinical trial studies the following conditions: Central Nervous System Tumor.
Who is sponsoring clinical trial NCT04852354?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04852354 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Central Nervous System Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Brain Slice Explants to Predict Drug Response in Brain Tumors
RECRUITING
-
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
RECRUITING · Phase 1
-
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
RECRUITING · Phase 1
-
Somatic Mosaicism in Twins Discordant for Childhood Cancer
RECRUITING
-
Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI